Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Dara-VRd for newly diagnosed myeloma: efficacy and safety data

Peter Voorhees • 4 Dec 2018
ASH 2018
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Lenalidomide
GRIFFIN

Peter Voorhees, MD, of Levine Cancer Institute, Charlotte, NC, discusses the safety and efficacy results for daratumumab, bortezomib, lenalidomide and dexamethasone (dara‐VRd) in ASCT-eligible newly diagnosed multiple myeloma patients from the Phase II GRIFFIN study (NCT02874742). Dr Voorhees reveals the encouraging tolerability, safety and response data from this trial.

More from Peter Voorhees

2:42
Promising cellular therapies emerging in multiple myeloma
Peter Voorhees • 30 Sep 2022
4:15
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Peter Voorhees • 30 Sep 2022
2:39
The role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
Peter Voorhees • 30 Sep 2022
4:51
The current frontline treatment strategy in multiple myeloma
Peter Voorhees • 30 Sep 2022

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals